This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Beaver, J. A. et al. N. Engl. J. Med. 384, e68 (2021).
US Food and Drug Administration Safety and Innovation Act; Public Law 112-144 (2012)
Kazandjian, D. et al. Clin. Cancer Res. 22, 1307–1312 (2016).
Howlader, N. et al. N. Engl. J. Med. 383, 640–649 (2020).
Ramagopalan, S. et al. BMC Med. 19, 209 (2021).
Singh, H. et al. JAMA Oncol. 7, 829–830 (2021).
Thein, K. Z. et al. Trends Cancer 7, 1074–1088 (2021).
Richardson, N. C. et al. Lancet Oncol. 23, 563–566 (2022).
Longo, D. L. N. Engl. J. Med. 371, 2227–2228 (2014).
Beaver, J. A. et al. N. Engl. J. Med. 386, 1297–1301 (2022).
V.S. is an Andrew Sabin Family Foundation Fellow at The University of Texas MD Anderson Cancer Center, acknowledges support of The Jacquelyn A. Brady Fund, is supported by a US National Institutes of Health (NIH) grant (no. R01CA242845 and R01CA273168). MD Anderson Cancer Center Department of Investigational Cancer Therapeutics is supported by the Cancer Prevention and Research Institute of Texas (no. RP1100584), the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (no. 1U01 CA180964), a NCATS (Center for Clinical and Translational Sciences) grant (no. UL1 TR000371), and the MD Anderson Cancer Center support grant (no. P30 CA016672). The content is solely the responsibility of the authors and does not necessarily represent the official views of the US NIH or FDA.
V.S. reports research funding or grant support for clinical trials from AbbVie, Agensys, Inc., Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines Corporation, Boston Biomedical, Inc., Boston Pharmaceuticals, Celgene Corporation, D3 Bio, Inc., Dragonfly Therapeutics, Inc., Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Inc., Incyte Corporation, Inhibrx, Loxo Oncology/ Eli Lilly, MedImmune, MultiVir, Inc., NanoCarrier, Co., National Comprehensive Cancer Network, NCI-CTEP, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche/Genentech, Takeda, Turning Point Therapeutics, UT MD Anderson Cancer Center and Vegenics Pty Ltd.; travel support from ASCO, ESMO, Helsinn Healthcare, Incyte Corporation, Novartis and PharmaMar; consultancy or advisory board participation for Helsinn Healthcare, Incyte Corporation, Loxo Oncology/Eli Lilly, MedImmune, Novartis, QED Therapeutics, Relay Therapeutics, Daiichi-Sankyo, and R-Pharm US; and other relationships with Medscape. L.W. receives consulting income from Bayer, Coherus, Curie Therapeutics, Eisai, Exelixis, Lilly and Novartis and has received fees for sitting on a Data Monitoring Committee for PDS Biotechnology. R.K. has received research funding from Biological Dynamics, Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda and TopAlliance; as well as consultant fees, speaker fees or is an advisory board member for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, Daiichi Sankyo, Inc., EISAI, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Roche, TD2/Volastra, Turning Point Therapeutics and X-Biotech; has an equity interest in CureMatch Inc., CureMetrix,and IDbyDNA; serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch. All other co-authors have no other conflicts.
About this article
Cite this article
Subbiah, V., Wirth, L.J., Kurzrock, R. et al. Accelerated approvals hit the target in precision oncology. Nat Med 28, 1976–1979 (2022). https://doi.org/10.1038/s41591-022-01984-z